AKBA

EQS-News: How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Retrieved on: 
Friday, September 23, 2022

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.

Key Points: 
  • Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.
  • In fact, each year, more people die from this silent killer than from breast or prostate cancer.
  • Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

Akebia Therapeutics to Present Virtually at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Thursday, September 1, 2022

CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference.
  • The hybrid conference will take place September 1214, 2022.
  • The presentation will be available on-demand beginning September 12, 2022 through the Investors section of Akebia's website at https://ir.akebia.com for approximately 90 days.
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

Akebia Therapeutics to Report Second Quarter Financial Results

Retrieved on: 
Tuesday, July 26, 2022

CAMBRIDGE, Mass., July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2022 on Thursday, August 4, 2022 following the close of financial markets.

Key Points: 
  • CAMBRIDGE, Mass., July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2022 on Thursday, August 4, 2022 following the close of financial markets.
  • Akebia will host a conference call on Thursday, August 4 at 4:30 p.m.
  • ET to discuss its financial results and provide a general business update.
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka

Retrieved on: 
Thursday, June 30, 2022

As part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55 million.

Key Points: 
  • As part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55 million.
  • "Otsuka has been a strong partner for many years, and we appreciate their desire to have an efficient transfer of the responsibilities back to Akebia.
  • Otsuka and Akebia will coordinate to transfer the MAA to Akebia through processes outlined by the EMA.
  • Vadadustat is also under review in the United Kingdom, Switzerland, and Australia through the Access Consortium.

Akebia Therapeutics to Present at Jefferies Healthcare Conference

Retrieved on: 
Friday, June 3, 2022

CAMBRIDGE, Mass., June 3, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m.

Key Points: 
  • CAMBRIDGE, Mass., June 3, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 10:30 a.m.
  • The Jefferies Healthcare Conference will take place June 8-10, 2022, in New York.
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.
  • Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference

Retrieved on: 
Thursday, May 19, 2022

An audio replay of the fireside chat will be available through the Investors section of Akebia's website at https://ir.akebia.com starting on May 24th and for approximately 90 days following the conference.

Key Points: 
  • An audio replay of the fireside chat will be available through the Investors section of Akebia's website at https://ir.akebia.com starting on May 24th and for approximately 90 days following the conference.
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.
  • Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts.
  • For more information, please visit our website at www.akebia.com , which does not form a part of this release.

Bronstein, Gewirtz & Grossman, LLC Reminds Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action Final Deadline and Last Few Hours to Actively Participate

Retrieved on: 
Friday, May 13, 2022

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

Key Points: 
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss in Akebia you have until May 13, 2022, to request that the Court appoint you as lead plaintiff.

AKEBIA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, May 12, 2022

Investors have until May 13, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 13, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases.
  • Akebias Phase 3 clinical programs for vadadustat include, among others, the PRO2TECT program in NDD-CKD patients with anemia (the PRO2TECT Program).
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.

AKBA FINAL DEADLINE FRIDAY: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important May 13 Deadline in Securities Class Action – AKBA

Retrieved on: 
Tuesday, May 10, 2022

WHAT TO DO NEXT: To join the Akebia class action, go to https://rosenlegal.com/submit-form/?case_id=4028 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Akebia class action, go to https://rosenlegal.com/submit-form/?case_id=4028 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2022.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

AKEBIA THERAPEUTICS, INC. (NASDAQ: AKBA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Akebia Therapeutics, Inc. (NASDAQ: AKBA)

Retrieved on: 
Tuesday, May 10, 2022

Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases.

Key Points: 
  • Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases.
  • Akebias Phase 3 clinical programs for vadadustat include, among others, the PRO2TECT program in NDD-CKD patients with anemia (the PRO2TECT Program).
  • If you purchased AKBA securities, and/or would like to discuss your legal rights and options please visit Akebia Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.